Glofitamab Cost-Effectiveness: Conditional Reim...

By HEOR Staff Writer

February 17, 2026

Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM